Search Results - "SHAH, Rashmi"

Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology by Shah, Rashmi R.

“…Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in…”
Get full text

Therapeutic importance of synthetic thiophene by Shah, Rashmi, Verma, Prabhakar Kumar

“…Thiophene and its substituted derivatives are very important class of heterocyclic compounds which shows interesting applications in the field of medicinal…”
Get full text

Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology by Curigliano, Giuseppe, Shah, Rashmi R.

“…Activation of phosphatidylinositol-3-kinase (PI3K) and downstream signalling by AKT/mammalian target of rapamycin (mTOR) modulates cellular processes such as…”
Get full text

Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas by Shah, Rashmi R.

“…Since the approval of the first molecularly targeted tyrosine kinase inhibitor (TKI), imatinib, in 2001, TKIs have heralded a new era in the treatment of many…”
Get full text

Chloroquine and hydroxychloroquine for COVID‐19: Perspectives on their failure in repurposing by Shah, Rashmi R.

“…What is known and Objective Non‐clinical studies suggest that chloroquine (CQ) and hydroxychloroquine (HCQ) have antiviral activities. Early clinical reports…”
Get full text

Addressing phenoconversion: the Achilles' heel of personalized medicine by Shah, Rashmi R., Smith, Robert L.

“…Phenoconversion is a phenomenon that converts genotypic extensive metabolizers (EMs) into phenotypic poor metabolizers (PMs) of drugs, thereby modifying their…”
Get full text

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit by Shah, Rashmi R., Morganroth, Joel

“…We previously reviewed the cardiovascular safety of 16 tyrosine kinase inhibitors (TKIs), approved for use in oncology as of 30 September 2012. Since then, the…”
Get full text

Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology by Shah, Rashmi R., Shah, Devron R.

“…Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) have dramatically improved progression-free survival in non-small-cell…”
Get full text

Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine by Shah, Rashmi R, Smith, Robert L

“…Phenoconversion transiently converts genotypic extensive metabolizers (EMs) into phenotypic poor metabolizers (PMs) of drugs, potentially with corresponding…”
Get full text

Genotype‐guided warfarin therapy: Still of only questionable value two decades on by Shah, Rashmi R.

“…What is known and objective Despite an apparently sound pharmacological basis, clinical studies of genotype‐guided warfarin dosing have yielded mixed and…”
Get full text

PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining by Luijsterburg, Martijn S., de Krijger, Inge, Wiegant, Wouter W., Shah, Rashmi G., Smeenk, Godelieve, de Groot, Anton J.L., Pines, Alex, Vertegaal, Alfred C.O., Jacobs, Jacqueline J.L., Shah, Girish M., van Attikum, Haico

“…The response to DNA double-strand breaks (DSBs) requires alterations in chromatin structure to promote the assembly of repair complexes on broken chromosomes…”
Get full text

Metamizole (dipyrone)‐induced agranulocytosis: Does the risk vary according to ethnicity? by Shah, Rashmi R.

“…Summary What is known and objective Based on spontaneous reports from Spain, it is claimed that the British, Irish and Scandinavians are at a greater risk of…”
Get full text

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives by Shah, Rashmi R., Morganroth, Joel, Shah, Devron R.

“…The introduction of small-molecule tyrosine kinase inhibitors (TKIs) in clinical oncology has transformed the treatment of certain forms of cancers. As of 31…”
Get full text

Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger? by Shah, Rashmi R.

“…Reversible posterior leukoencephalopathy syndrome (RPLS), also known frequently as posterior reversible encephalopathy syndrome (PRES), is a characteristic…”
Get full text

Drug‐induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives by Shah, Rashmi R

“…ATP‐dependent potassium channel openers such as pinacidil and levcromakalim have long been known to shorten action potential duration and to be profibrillatory…”
Get full text

Drug‐induced QT interval prolongation: does ethnicity of the thorough QT study population matter? by Shah, Rashmi R.

“…Inter‐ethnic differences in drug responses have been well documented. Drug‐induced QT interval prolongation is a major safety concern and therefore, regulatory…”
Get full text

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval) by Shah, Rashmi R., Morganroth, Joel, Shah, Devron R.

“…The development of tyrosine kinase inhibitors (TKI) represents a major milestone in oncology. However, their use has been found to be associated with serious…”
Get full text

Dealing with Global Safety Issues: Was the Response to QT-Liability of Non-Cardiac Drugs Well Coordinated? by Stockbridge, Norman, Morganroth, Joel, Shah, Rashmi R., Garnett, Christine

“…Drug-induced torsade de pointes (TdP) is a potentially fatal iatrogenic entity. Its reporting rate in association with non-cardiac drugs increased…”
Get full text

Synthesis of thiophene derivatives and their anti-microbial, antioxidant, anticorrosion and anticancer activity by Shah, Rashmi, Verma, Prabhakar Kumar

“…Background A new series of thiophene analogues was synthesized and checked for their in vitro antibacterial, antifungal, antioxidant, anticorrosion and…”
Get full text

Precision medicine: does ethnicity information complement genotype-based prescribing decisions? by Shah, Rashmi R., Gaedigk, Andrea

“…Inter-ethnic differences in drug response are all too well known. These are underpinned by a number of factors, including pharmacogenetic differences across…”
Get full text